What makes Yuvezzi different from other presbyopia drops?

Yuvezzi is the first and only combination presbyopia drop. It pairs carbachol (a miotic for pupil constriction) with brimonidine (which prevents redness and helps lock the pupil in its constricted state). The anti-redness benefit is unique — other drops often cause visible red eyes.

Is Yuvezzi safe for long-term use?

Yuvezzi has the longest safety study (BRIO II, 12 months, 800+ patients) of any presbyopia drop. Over 72,000 treatment days, no serious treatment-related adverse events were reported. The rate of eye redness was only 2.8%, dramatically lower than the 10.7% with carbachol alone.

Yuvezzi Eye Drops Review: First Combination Presbyopia Drop (2026)

The Dual-Agent Approach

Yuvezzi is the first fixed-dose combination therapy approved for presbyopia, leveraging two complementary mechanisms:[BioPharma Dive]

Carbachol 2.75%

A potent cholinergic miotic that constricts the pupil to create the pinhole effect for near-vision improvement. Carbachol is a direct parasympathomimetic with a longer duration of action than pilocarpine.

Brimonidine 0.1%

An alpha-2 adrenergic agonist with two important functions: (1) it inhibits the iris dilator muscle, "locking" the pupil in its constricted state for up to 10 hours, and (2) it's a vasoconstrictor that reduces eye redness rather than causing it.[European Biotech]

💡 Why Brimonidine Matters

Brimonidine is already marketed separately as Lumify (over-the-counter redness relief). In Yuvezzi, it serves double duty: extending the miotic effect AND counteracting the red-eye side effect that plagues other presbyopia drops. The BRIO II trial showed only 2.8% redness with Yuvezzi vs 10.7% with carbachol alone.[Ophthalmology 360]

BRIO Trial Results

Yuvezzi's approval was based on the BRIO I and BRIO II Phase III trials. BRIO II is especially significant: it enrolled over 800 patients for 12 months — the longest safety study in the category.[Ophthalmology 360]

BRIO II Key Results

Study duration 12 months (longest in category)

Total treatment days 72,000+

Serious treatment adverse events None reported

Redness rate (combo) 2.8%

Redness rate (carbachol alone) 10.7%

Duration of near-vision improvement 8-10 hours

Sources: Ophthalmology 360, Fierce Pharma

The Anti-Redness Advantage

For many patients, the biggest deterrent to using presbyopia drops isn't dim vision or headaches — it's the "stoned" look. Forum users frequently describe looking visibly impaired for up to an hour after instillation, creating a social/professional barrier.[Reddit]

Yuvezzi directly addresses this by including brimonidine — the same vasoconstrictor ingredient in OTC Lumify. Instead of causing redness, your eyes may actually appear whiter and brighter after using Yuvezzi. This is a significant practical advantage for professionals who need to look alert and attentive at work.[BioPharma Dive]

Side Effects & Safety

HeadacheLow

Eye redness2.8% (actively reduced)

Dim visionModerate (pupil constriction)

12-month serious adverse eventsNone reported

As with all miotic drops, standard safety considerations apply: nighttime driving is discouraged, and patients with high myopia, lattice degeneration, or narrow angles should be screened before starting. For the full safety analysis, see our comprehensive side effects guide.

The Bottom Line

Yuvezzi brings genuine innovation with its dual-mechanism approach. While VIZZ leads on raw efficacy (71% responders), Yuvezzi's unique strengths are its anti-redness benefit and its unmatched 12-month safety dataset.

Best for:

• Professionals concerned about the "red eye" appearance
• Patients wanting the longest available safety data
• People who value cosmetic appearance alongside vision correction
• Those seeking all-day coverage (10 hours)

For the best long-term results, consider combining Yuvezzi with Gabor patch brain training — drops fix the optics while training fixes the neural processing. Read the full comparison →

Yuvezzi: The First Combination Presbyopia Drop